XY0YX37
Introduction Extracorporeal to New Technology Group 7 with Nafamostat Anticoagulant, External Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | Y Extracorporeal |
| Operation | 0 Introduction |
| Body Part | Y Extracorporeal |
| Approach | X External |
| Device | 3 Nafamostat Anticoagulant |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers Introduction procedures performed on blood or another substance outside the body, where a therapeutic, diagnostic, nutritional, physiological, or prophylactic agent is put into that extracorporeal circuit rather than directly into the patient. In practice, this often means treating blood as it passes through an external device - for example, exposing it to a filtering, adsorption, or light-based therapy - before it's returned to the body, or introducing an agent into another extracorporeal system such as a perfusion or dialysis circuit.
This approach is used when a substance needs to interact with blood or another body fluid in a controlled external environment, often to remove harmful compounds, deliver a treatment more precisely, or support a patient during critical illness. Because it sits in New Technology, the specific substance or delivery method reflects a recently approved product or technique.
Anatomy & Axis Detail
Extracorporeal
Introduction into the extracorporeal body part refers to administering a new-technology substance directly into a device or circuit functioning outside the patient's body, such as an extracorporeal membrane oxygenation circuit, a dialysis circuit, or a similar perfusion apparatus, rather than into the patient's own vasculature or tissue. This distinction matters because agents such as anti-infectives, anticoagulants, or other novel compounds are sometimes added to the circuit itself to treat or prevent circuit-related complications, including biofilm formation or clot development within the tubing and oxygenator, without necessarily being intended as a systemic treatment delivered through the patient's own vessels. Documentation should make clear that the substance was introduced into the extracorporeal apparatus rather than through a vascular access site into the patient, since that is what differentiates this qualifier from vein, artery, or other anatomic introduction sites.
Approach: External
External approach in New Technology applies to procedures performed directly on the skin, mucous membranes, or via direct visualization without penetrating a body cavity, such as applying or activating a device against the body surface. It contrasts with Percutaneous approaches, which require instrument entry through the skin rather than surface-level contact.
Device / Substance / Technology: Nafamostat Anticoagulant
This value identifies nafamostat, a synthetic protease inhibitor used as an anticoagulant, most notably as a regional anticoagulant within extracorporeal circuits such as continuous renal replacement therapy, particularly for patients at elevated bleeding risk where heparin is undesirable. It differs from heparin-based anticoagulation by its distinct mechanism and short half-life, allowing more localized, reversible anticoagulant effect.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coding requires documentation that identifies the specific substance introduced, confirms it was introduced into an extracorporeal circuit rather than directly into the patient's body, and names the approved New Technology product used to deliver it. The record should also make clear the intent - therapeutic, diagnostic, nutritional, or prophylactic - since that shapes which specific code applies.
A common mistake is coding this as a standard Administration or Introduction procedure from another PCS section when the substance and device actually match an approved New Technology entry, or missing the extracorporeal element and coding it as if the substance were introduced directly into the bloodstream. Coders should also watch for cases where the extracorporeal treatment is bundled into a larger procedure, such as an extracorporeal support circuit, and needs to be coded separately.
Commonly Confused With
This family is frequently confused with standard Administration section codes for introducing substances into the body, and with extracorporeal Assistance or Performance procedures that support a physiological function rather than deliver a substance. The distinguishing feature is that this code captures the act of introducing a substance into an external circuit or fluid, not the act of supporting or replacing an organ function.